PubMed Health⌕ Search

Biomedical subjects

R Salinas

Publications and source records attributed to R Salinas.

At least 19 recordsLinked to original sources
PubMed2006

Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients.

OBJECTIVE: Vascular endothelial growth factor (VEGF) promotes normal and pathological angiogenesis. VEGF is a chemotactic factor for macrophages and vascular smooth muscle cells, and induces synthesis of metalloproteinases and adhesion molecules. VEGF expression is regulated by hypoxia, cytokines, oncogenes, and oxidized low-density lipoprotein (LDL). The purpose of this study was to determine the relationship between levels of lipid parameters and VEGF, to investigate whether pravastatin treatment influences VEGF serum concentrations, and to examine the relationship between VEGF and the variations in post-treatment lipid and inflammatory parameters. MATERIAL AND METHODS: Eighteen patients aged 48+/-6.8 years with total cholesterol (TC) >6.1 mmol/L comprised the hypercholesterolemic group. The controls included 12 individuals aged 50+/-7.4 years with TC <5.1 mmol/L. TC, high-density lipoprotein cholesterol (HDLC), triglycerides, LDLC, C-reactive protein (CRP), and VEGF were determined in both groups at baseline, and in the hypercholesterolemic group after 4 months of treatment with 20 mg/day pravastatin. RESULTS: A significant correlation was observed between concentrations of VEGF and TC, LDLC and TG, and a significant difference in VEGF concentration was observed between the control group (mean 142 ng/L) and the hypercholesterolemic group (mean 272.9 ng/L). A significant decrease was observed in TC (14.7 %), LDLC (21.5 %), CRP (22.7 %), and VEGF (14.8 %) after 4 months of treatment with pravastatin. CONCLUSIONS: A relationship was found between serum levels of VEGF and most atherogenic lipoproteins. In patients with hypercholesterolemia treated with pravastatin, a reduction in VEGF and CRP was seen in addition to lipid decreases.

Adult↗
PubMed2000

Patch angioplasty versus primary closure for carotid endarterectomy.

BACKGROUND: Carotid patch angioplasty (with either a venous or a synthetic patch) may reduce the risk of carotid artery restenosis and subsequent ischaemic stroke. OBJECTIVES: The objective of this review was to assess the effect of routine or selective carotid patch angioplasty compared to carotid endarterectomy with primary closure. SEARCH STRATEGY: We searched the Cochrane Stroke Group trials register, Medline (1966 to 1995), Embase (1980 to 1995) and Index to Scientific and Technical Proceedings (1980 to 1994). We handsearched Annals of Surgery (1981 to 1995), British Journal of Surgery (1985 to 1995), European Journal of Vascular and Endovascular Surgery (1987 to 1995) and World Journal of Surgery (1978 to 1995). SELECTION CRITERIA: Randomised trials comparing carotid patch angioplasty with primary closure in any patients undergoing carotid endarterectomy. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed eligibility, trial quality and extracted the data. MAIN RESULTS: Six trials involving 794 patients and 882 operations were included. The quality of trials was generally poor. Follow-up varied from hospital discharge to five years. Carotid patch angioplasty showed a reduction in the risk of stroke of any type, ipsilateral stroke, and stroke or death, during the perioperative period and longterm follow-up. However, data were not available from all trials, the number of events was small and there was significant loss to follow-up. Patching appeared to reduce the risk of perioperative arterial occlusion (six trials, odds ratio 0.17, 95% confidence interval 0.06 to 0.46). Patching was also associated with decreased restenosis during longterm follow-up in five trials, (odds ratio 0.32, 95% confidence interval 0.19 to 0.53). However, these results are uncertain because of loss to follow-up and the small number of events. Very few arterial complications, including haemorrhage, infection, cranial nerve palsies and pseudo-aneurysm formation were recorded with either patch or primary closure. REVIEWER'S CONCLUSIONS: Limited evidence suggests that carotid patch angioplasty may lower the risk of perioperative arterial occlusion and restenosis. It is unclear whether this reduces the risk of death or stroke.

Blood Vessel Prosthesis↗
PubMed2000

Routine or selective carotid artery shunting for carotid endarterectomy (and different methods of monitoring in selective shunting).

BACKGROUND: Temporary interruption of blood flow during carotid endarterectomy can be avoided by using a shunt across the clamped section of the carotid artery. This may improve outcome. OBJECTIVES: The objective of this review was to assess the effect of routine versus selective shunting during carotid endarterectomy, and to assess the best method for selecting patients for shunting. SEARCH STRATEGY: We searched the Cochrane Stroke Group trials register, Medline (1966 to 1994), Embase (1980 to 1995) and Index to Scientific and Technical Proceedings (1980 to 1994). We handsearched Annals of Surgery (1981 to 1995), British Journal of Surgery (1985 to 1995), European Journal of Vascular Surgery (1988 to 1995) and World Journal of Surgery (1978 to 1995). SELECTION CRITERIA: Randomised and quasi-randomised trials of routine shunting compared with no shunting, and trials that compared different shunting policies in patients undergoing carotid endarterectomy. DATA COLLECTION AND ANALYSIS: Two reviewers independently applied the inclusion criteria. The data were extracted by one reviewer and double-checked. Trial quality was assessed. MAIN RESULTS: Three trials were included. Two trials involving 590 patients compared routine shunting with no shunting. The other trial involving 131 patients compared shunting with a combination of electroencephalographic and carotid pressure measurement, with shunting by carotid pressure measurement alone. Allocation was adequately concealed in one trial, and one trial was quasi-randomised. Analysis was by intention-to-treat where possible. For routine versus no shunting, there was no significant difference in the rate of all stroke, ipsilateral stroke or death up to 30 days after surgery, although data were limited. There was no significant difference between the risk of ipsilateral stroke in patients selected for shunting with the combination of electroencephalographic and carotid pressure assessment compared to pressure assessment alone, although again the data were limited. REVIEWER'S CONCLUSIONS: The data presently available are too limited to either support or refute the use of routine or selective shunting in carotid endarterectomy. Large scale randomized trials using no shunting as the control group are required. No one method of monitoring in selective shunting has been shown to produce better outcomes.

Arteriovenous Shunt, Surgical↗
PubMed2000

Drugs for treating neurocysticercosis (tapeworm infection of the brain).

BACKGROUND: Anthelminthic drugs may shrink brain cysts in neurocysticercosis, but can also cause severe adverse effects. OBJECTIVES: The objective of this review was to assess the effects of drug treatment in human neurocysticercosis in relation to survival, cyst persistence, subsequent seizures and hydrocephalus. SEARCH STRATEGY: We searched the Cochrane Infectious Diseases Group trials register and Medline. We contacted researchers and experts in the field and drug manufacturers. SELECTION CRITERIA: Randomised or quasi-randomised trials comparing a cysticidal drug with a placebo or a control group receiving symptomatic therapy, in patients with neurocystercosis. DATA COLLECTION AND ANALYSIS: Assessment of trial quality and data extraction was done independently by two reviewers. MAIN RESULTS: Four studies involving 305 people met the inclusion criteria. None reported on withdrawal of anticonvulsant therapy, headache relief, disability or death as outcomes. A difference just approaching significance was detected between cysticidal therapy and placebo in relation to cyst persistence up to six months (relative risk 0.83, 95% confidence interval 0.70 to 0.99). Two trials reported on seizures after one to two years follow-up and found no difference (relative risk 0.95, 95% 0.59 to 1.51). There was no difference detected for hydrocephalus (relative risk 2.19, 95% confidence interval 0.29 to 16.55). REVIEWER'S CONCLUSIONS: There is insufficient evidence to assess whether cysticidal therapy in neurocysticerosis is associated with beneficial effects.

Albendazole↗
PubMed2000

Bell's palsy.

Explore the source record for details and available documents.

Acyclovir↗
PubMed1999

Treating neurocysticercosis medically: a systematic review of randomized, controlled trials.

OBJECTIVE: To summarize the evidence from randomized controlled trials on the effects of cysticidal therapy used for treating human cysticercosis. METHODS: Published and unpublished studies in any language identified through MEDLINE (1966 - June 1999) specialized databases, abstracts, proceedings and contact with experts were analysed. Those which compared, using randomized or quasi-randomized methods, any cysticidal drug with placebo or symptomatic therapy were entered in the study. Data were extracted independently by two reviewers and trial quality assessed. Meta-analysis using fixed effects models calculated provided there was no significant heterogeneity, expressed as relative risk. RESULTS: Four trials met the inclusion criteria, treating intraparenchymatous neurocysticercosis with either albendazole or praziquantel compared to placebo or no treatment. In the two trials reporting clinical outcomes, treatment was not associated with a reduction in the risk of seizures, although numbers were small (RR 0.95, 95% CI 0.59-1.51). Four trials reported radiological outcomes, and cysticidal treatment was associated with a lower risk of cyst persistence of scans taken within six months of start of treatment (RR 0.83, 95% CI 0.70-0.99). Subsidiary analysis assuming different outcomes in patients lost to follow-up did not alter the findings of the main analysis. CONCLUSIONS: There is insufficient evidence to determine whether cysticidal therapy is of any clinical benefit to patients with neurocysticercosis. The review does not exclude the possibility that more patients remain seizure-free when treated with cysticidal drugs. Further testing through placebo-controlled trials is required.

Albendazole↗
PubMed1999

[Heart rate and physical activity to assess energy expenditure in children].

The aim of the present study was to validate assessment of oxygen consumption (VO2) from heart rate (HR) and physical activity (PA) electronically recorded. Every minute, mean VO2 were validated with indirect calorimetry. We studied 25 children (12 girls, 13 boys), 12.1 +/- 0.7 years old. Measurements were made during about 60 minutes while kids were supine, sitting, standing and walking at four intensities. Minute by minute heart rate was converted to VO2 and energy expenditure using 2 different functions for active and inactive situations. A linear function (VO2 = a + beta HR) was used when counts were 7 or higher and HR higher than a prefixed point (intersection between the 2 line functions). A nonlinear equation (VO2 = a + beta HR3) was used in the remaining minutes. Mean predicted VO2 for every minute were similar to measured VO2 (2 ways interaction ANOVA, p = 0.99). Mean VO2 correlated significantly with VO2 predicted by equation (r = 0.99, p < 0.01). High degree of agreement was found (Bland-Altman comparisons). Combined heart rate and physical activity predicted oxygen consumption with a precision similar to the indirect calorimetric method.

Adolescent↗
PubMed1997

Oral transmucosal fentanyl citrate as an additional premedicant for adult cardiac surgery patients.

OBJECTIVE: To investigate the efficacy of a combination of midazolam and oral transmucosal fentanyl citrate (OTFC) as a preoperative medication for adult cardiac surgery patients compared with the use of midazolam alone. DESIGN: A randomized, prospective study. SETTING: University teaching hospital. PARTICIPANTS: Patients scheduled for elective coronary artery bypass surgery. INTERVENTIONS: All patients were given 50 micrograms/kg of midazolam intramuscularly in their rooms. Group I received 300 micrograms of OTFC Oralet (Anesta Corp, Salt Lake City, UT) if they weighed less than 70 kg and 400 micrograms of OTFC Oralet if they weighed more than 70 kg. Group II received a placebo Oralet. A radial artery catheter, two internal jugular venous catheters, and a pulmonary artery catheter inserted through one of the internal jugular catheters were placed in each study patient. Fentanyl was administered intravenously as a rescue drug. MEASUREMENTS AND MAIN RESULTS: Ninety percent of midazolam/OTFC patients reported feeling no pain during catheter placement, compared with 50% of midazolam/placebo patients. Fifty percent of the placebo group required fentanyl supplement of 50 micrograms intravenously because of complaints of pain, compared with 10% of the OTFC group. The midazolam/OTFC group scored approximately 20% better than the placebo group in the independent observer score of patient analgesia and the anesthesiologist rating for ease of invasive catheter placement. No myocardial ischemic events were noted in either group as determined by electrocardiogram. All patients found the Oralet mode of delivery very acceptable. CONCLUSIONS: The OTFC Oralet provides effective analgesia and sedation when combined with midazolam for invasive catheter placement in adult cardiac surgery patients. The OTFC Oralet with its gradual onset lessens the possibility of overmedicating with fentanyl, and it offers a very acceptable mode of delivery for a preemptive analgesic.

Administration, Oral↗
PubMed1997

A systematic review of the randomised trials of carotid patch angioplasty in carotid endarterectomy.

OBJECTIVES: To determine whether patch angioplasty is more effective than primary closure in carotid endarterectomy, and whether one type of patch is better than another. DESIGN: Systematic review of the randomised trials. MATERIALS: Trials were identified from the Cochrane Stroke Review Group database plus additional handsearching, electronic searching, and personal contact. METHODS: Two authors independently selected studies for inclusion and extracted details of trial quality and data on the following outcomes: any stroke; stroke ipsilateral to the operated artery; death; occlusion or restenosis, and other significant arterial complications. Meta-analysis of odds ratios (OR) was performed using the Peto method. RESULTS: Six trials (882 operations) compared routine patching with primary closure. Routine patching was associated with significant reductions in the risks of ipsilateral stroke during the perioperative period (OR 0.34, 95% CI 0.15-0.76) and during long-term follow-up (OR 0.38, 95% CI 0.16-0.88). Significant reductions in the odds of any stroke, stroke or death, acute arterial occlusion and long-term restenosis were also found. However, these results were based on very small numbers of outcome events and may be biased by losses to follow-up and publication bias. Three trials (326 operations) compared the use of polytetrafluoroethylene patches with venous patches. There were too few events (strokes, deaths, arterial complications) to determine whether there were significant differences between the patch materials. Fewer pseudoaneurysms occurred in those who received synthetic patches but the clinical consequence of this was unclear. CONCLUSIONS: Routine carotid patch angioplasty was associated with promising reductions in the risks of ipsilateral stroke and death, but the results should be interpreted cautiously because of the small number of outcome events, significant losses to follow-up, and poor trial methodology. Ideally, a large definitive trial should be performed. There is insufficient evidence to support the preferential use of one particular type of patch versus another.

Aged↗
PubMed1996

[Organizational models for the hematology areas of the district hospitals of Catalonia].

PURPOSE: The haematological assistance in Catalonia is based upon the district hospitals, in the first step, and the stage III hospitals located usually in higher population nuclei, in the second step. The purpose of this work was to analyse the resources of the "primary haematological assistance" network provided by the district hospitals, to evaluate them and to propose a model for their organisation. MATERIAL AND METHODS: An enquiry was carried out to all members of the Grup de Treball d'Hospitals Comarcals de Catalunya (Catalonia's District Hospitals Task Force). The evaluable data included demographic figures of the population assisted, personnel of each haematological area, organising structure, clinical activity, cytomorphology, blood banks, laboratories and continuous formation activities. RESULTS: The enquiry was answered by 15 of the 21 district hospitals (71.4%) with haematologists in Catalonia. The population assisted in those hospitals is 2,100,000 (ranging between 55,000 an 450,000). All centres are integrated in the National Health network. Eleven of the hospitals analysed have only one haematologist (73.3%). If his dedication is 100% of the time, this would represent a doctor for 105,000 people. The time devoted to work is 690 hours a week for all the population, with a mean of 3,043. Four patients assisted per hour. The total number of hospital beds is 3,353 (50-450), with a mean number of 1 haematologist for every 167.6 beds. The number of patients hospitalized due to blood diseases ranges between 3 and 13 per month. Six of the 15 centres are adjunct to the outpatient clinic. Two centres have a blood bank and 7 have developed an autotransfusion programme. All the centres but one perform oral anticoagulant treatment follow-up, the number of patients assisted ranging from 20 to 210 per week. None of the hospitals has a separate Haematology Service; in most of them haematology is structurally and functionally dependent from Laboratories and in some there is a mixed Laboratory/Internal Medicine functional organisation, depending of the Medical Direction. No haematologist is ever on call specifically for his specialty. Continuous formation activities are carried out in 9 of the 15 centres (60%). COMMENT: Several measures are proposed to improve the haematological assistance, acting on different levels: continuous formation, patient flows and circuits, resident doctors training, anticoagulant treatment network, organisation models, credit cards from the Spanish Association of Haematology.

Adult↗
PubMed1995

Does the angiographic appearance of a carotid stenosis predict the risk of stroke independently of the degree of stenosis?

We aimed to determine whether the angiographic characteristics of recently symptomatic carotid stenosis predict risk of subsequent ischaemic stroke independently of the degree of stenosis. First, two observers compared the angiographic characteristics of patients who subsequently suffered a carotid distribution ischaemic stroke ipsilateral to the stenosis (n = 50) with those of stroke-free controls (n = 100) matched for the degree of stenosis of the symptomatic internal carotid artery. No significant differences were found. Secondly, seven independent observers attempted to identify the angiograms of 50 patients who subsequently suffered a stroke from those of 50 stroke-free controls matched for degree of stenosis, age and sex. None of the observers identified the stroke case more often than was expected by chance alone. We conclude that clinicians cannot differentiate between 'high risk' and 'low risk' carotid stenoses on the basis of angiographic characteristics other than the degree of stenosis.

Carotid Artery, Internal↗
PubMed1995

A new formula for prenatal ultrasonographic weight estimation in extremely preterm fetuses.

A new formula for the prenatal estimation of the weight of extremely preterm fetuses was derived using ultrasound measurements and birth weights of 73 premature infants delivered before 30 completed weeks of pregnancy and weighing between 400 and 1,680 g at birth. The actual birth weight lay within +/- 15% of the estimated weight calculated with this formula in 92% of the cases. Preliminary testing of the reliability of the formula was performed on a further test group of 19 nonselected cases. The formula developed in this study offers a reliable and simple method of prenatal estimation of fetal weight between 23 and 30 weeks of gestation.

Body Weight↗
PubMed1995

[Macrosomia and death. Relationship with maternal diabetes].

The incidence of macrosomic newborns and fetal death and its possible relation to maternal diabetes mellitus (DM) was registered during six months at the Hospital de Ginecoobstetricia "Dr. I. Morones", IMSS. Both criteria for macrosomia 4,000 g and 4,500 g, were taken for data collection. We had a total of 15,217 newborns, of these, 872 (5.73%), weighed > 4,000 g, and there were 42 mothers with DM, 4.2% of the group. Taking 4,500 g as criteria for macrosomia, there were 105 newborns (0.69%) of the total and there were 8 mothers with DM, 7.6%. 501 of the pregnancies finished by cesarean section and 337 by delivery. There were 151 fetal deaths, 9.9 for 1,000 newborns, eight fetuses had a weight over 4,000 g, and two mothers had DM. It is concluded that maternal diabetes mellitus occurred in less than 5% of the mothers with macrosomic newborns (> 4,000 g). The incidence of macrosomia is lower than in European populations. Fetal deaths were higher than expected because this hospital concentrates patients with obstetrical complications.

Female↗
PubMed1993

Trends and survival in AIDS-associated malignancies.

Data from 1569 AIDS cases reported to the population-based AIDS Registry of Catalonia have been analysed to describe the epidemiology and temporal evolution of both Kaposi's sarcoma (KS) and non-Hodgkin lymphoma (NHL). Of the 1569 cases reported, 53 (3.4%) presented with NHL and 135 (8.6%) with KS. KS cases were more frequent among homosexual/bisexual men and the age of KS cases was significantly higher than all others presenting diseases (38.22 years). NHL cases were more frequently among men but no significant age difference was found. The percentage of KS over time decreased significantly only among intravenous drug users. Cases presenting with a NHL had by far the worst prognosis (median survival time = 169 days). Biases affecting the measurement of AIDS associated malignancies (AAM) using surveillance data are analysed. The prevalence of AAM will increase during the next few years, and NHL may be one of the leading causes of death among AIDS patients in the near future.

Acquired Immunodeficiency Syndrome↗